Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.

Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.

Item
http://www.wikidata.org/entity/Q33416977
Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with SulfasalazineA stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.Current achievements and future perspectives of metronomic chemotherapy.Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial.Castration is a prerequisite for the inhibitory effect of metronomic chemotherapy on the growth of experimental castration-resistant prostate cancer.Local Radiotherapy Affects Drug Pharmacokinetics-Exploration of a Neglected but Significant Uncertainty of Cancer Therapy.Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
P2860

Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.

Item
http://www.wikidata.org/entity/Q33416977
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Docetaxel plus oral metronomic ...... tant prostate cancer patients.
@ast
Docetaxel plus oral metronomic ...... tant prostate cancer patients.
@en
type
label
Docetaxel plus oral metronomic ...... tant prostate cancer patients.
@ast
Docetaxel plus oral metronomic ...... tant prostate cancer patients.
@en
prefLabel
Docetaxel plus oral metronomic ...... tant prostate cancer patients.
@ast
Docetaxel plus oral metronomic ...... tant prostate cancer patients.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Docetaxel plus oral metronomic ...... stant prostate cancer patients
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698